← back to search

José Mayordomo

University of Colorado Anschutz Medical Campus · US
🔎 Find collaborators in Oncology · Pulmonary and Respiratory Medicine →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, and Cancer Treatment and Pharmacology.
h-index
57
citations
18,867
works
231
NIH funding
—
primary concept
Medicine
email
✉ Find email ↗

Recent publications

Supplementary Table S3 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025cited by 0position: contributordoi
Supplementary Fig. S1 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025cited by 0position: contributordoi
Supplementary Table S1 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025cited by 0position: contributordoi
Supplementary Fig. S3 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025cited by 0position: contributordoi
Supplementary Fig. S2 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025cited by 0position: contributordoi
Data from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025cited by 0position: contributordoi
Supplementary Table S2 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025cited by 0position: contributordoi
Supplementary Fig. S3 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024cited by 0position: contributordoi
Supplementary Table S1 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024cited by 0position: contributordoi
Supplementary Table S2 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024cited by 0position: contributordoi
Supplementary Fig. S1 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024cited by 0position: contributordoi
Supplementary Table S1 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024cited by 0position: contributordoi
Supplementary Table S2 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024cited by 0position: contributordoi
Supplementary Table S3 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024cited by 0position: contributordoi
Supplementary Fig. S1 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024cited by 0position: contributordoi
Supplementary Fig. S2 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024cited by 0position: contributordoi
Supplementary Fig. S2 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024cited by 0position: contributordoi
Data from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024cited by 0position: contributordoi
Supplementary Table S3 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024cited by 0position: contributordoi
Supplementary Fig. S3 from Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
2024cited by 0position: contributordoi
Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer.
2023cited by 10position: contributordoi
Supplementary Fig. S3 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2023cited by 0position: contributordoi
Supplementary Fig. S3 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2023cited by 0position: contributordoi
Supplementary Table S1 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2023cited by 0position: contributordoi
Supplementary Table S1 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2023cited by 0position: contributordoi
Supplementary Table S3 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2023cited by 0position: contributordoi
Supplementary Fig. S1 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2023cited by 0position: contributordoi
Supplementary Fig. S3 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2023cited by 0position: contributordoi
Supplementary Fig. S2 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2023cited by 0position: contributordoi
Data from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Peter Kabos · University of Colorado Health47 papers (2023–2025)William J. Gradishar · Northwestern University47 papers (2023–2025)— · 47 papers (2023–2025)— · 47 papers (2023–2025)Ursa Brown-Glaberman · University of New Mexico47 papers (2023–2025)— · 47 papers (2023–2025)Andrew J. Brenner · The University of Texas at San Antonio Health Science Center47 papers (2023–2025)— · 47 papers (2023–2025)Virginia Borges · University of Colorado Health47 papers (2023–2025)Elena Shagisultanova · University of Colorado Denver47 papers (2023–2025)— · 47 papers (2023–2025)Dexiang Gao · Northeast Ohio Medical University47 papers (2023–2025)— · 47 papers (2023–2025)Hannah Parris · University of Colorado Anschutz Medical Campus47 papers (2023–2025)Tessa Mcspadden · 47 papers (2023–2025)Alison Stopeck · University of Arizona47 papers (2023–2025)Guðmar Þorleifsson · deCODE Genetics (Iceland)1 papers (2020–2020)Sun Young Rha · Incheon Medical Center1 papers (2022–2022)— · 1 papers (2020–2020)Christopher I. Amos · UNM Comprehensive Cancer Center1 papers (2012–2012)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Oncology · Pulmonary and Respiratory Medicine →